Revolutionary Device in Non-Small Cell Lung Cancer (NSCLC) Detection and Beyond

作者:动脉网 2016-02-17 11:25

{{detail.short_name}} {{detail.main_page}}

{{detail.description}} {{detail.round_name}} {{detail.state_name}}

{{detail.province}}-{{detail.city}}
{{detail.setup_time}}
融资金额:{{detail.latest_event_amount}}{{detail.latest_amount_unit}}
投资方: · {{item.latest_event_tzf_name}}
企业数据由提供支持
查看

360截图20160217111217643


Lung cancer is the second most common cancer in both men and women (not counting skin cancer) and is by far the leader in cancer deaths among both men and women. In 2008 lung cancer replaced liver cancer as leading cause of deaths in China. The registered lung cancer mortality rate has increased 464.85% in the past three decades in the country of the red dragon. Non-small cell lung cancer (NSCLC) accounts for 85% of overall lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of NSCLC.Most doctors agree that prevention and early detection are often the best way to battle lung cancer. Not long ago, three different kinds of lung cancer tests could be recommended by your doctor: Imaging testing, Sputum cytology and biopsy. Yet these diagnosis methods are bothersome and costly. Only when there is a reasonable probability of having cancer will these diagnosis methods be utilized, i.e., after the detection of a suspicious agent in your organism. A vast majority of patients do not realize they have developed cancer until it is too late. Consequently, the lung cancer survival rate has remained very small in past decades. Since 2011, however, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCC) have recommended Epidermal Growth Factor Receptor (EGFR) testing for patients with advanced (NSCLC). Simply said, this recent method treats lung cancer through EGFR, more concretely, via EGFR-tyrosine kinase inhibitors such as geftinib or erlotiniv. Although it has improved the survival rate considerably, the EGFR mutation test does not differ from its predecessors in other aspects and similarly requires a high level of resources, numerous professional staff and is time-consuming.


图片6


It is in this landscape that a new biotechnological start-up named Yihuo Bio steps in. The company is headquartered in USA, and is building in a manufacturing factory in China to produce en mass a new device that could revolutionize the lung cancer field as soon as the summer of 2016. They will make an official product presentation in the next ASCO conference this coming June in Chicago, USA.The company is run by Dr. Wei Liao, Dr. Liao, a happily married family man studied chemistry in the most prestigious Chinese university in Beijing. He followed his studies in China with post-graduate studies in medicine at UCLA. As he states, he has a clear vision of the future of his company. "The more people that can benefit from this new technology, the better," he earnestly states. "We own the patent but we do not mind sharing with anyone who has the same vision as us; we want to help as many people as possible," he adds. They plan to start producing in China and spread rapidly throughout the domestic market –the second-largest economy in the world. As soon as 2017, they plan to penetrate into other regions.


易活生物CEO廖玮4


The device is convenient in its usage but complex in its structure. It can detect most of the common lung cancer subtypes, non-small cell lung cancer through analysis of a simple body fluid. This process has been called a "liquid biopsy" and gives the same result as a regular biopsy without the invasive drawbacks. The advantages of this new lung cancer diagnosis method compared to previous ones are self-evident. Aside from it being non-invasive, it has proven inexpensive efficient.-It can diagnose most common lung cancer subtypes in as little as 30 minutes. In addition, tests have shown it presents a high detection accuracy rate, close to 99%.Regarding its structure-, it consists in the adaptation of a saliva-based EGFR mutation detection into an electrochemical platform integrating sensitive and specific multiplexing lab assay. The latter is named electric field-induced release and measurement (EFIRM). The combination of both structures and the final product name is eLB. This product adaptation has a significant meaning- to match Dr. Liao´s significant vision. Using an analogy-: he wants the platform to become the new "Apple Store" of gene mutation disease detection. The platform will be free. The idea is to be able to detect any disease able to be detected through gene mutation in the near future. The device would be comprised of numerous tests ticks. Each test tick can measure an EGFR mutation and is disposable. Its expected price is half' of current diagnosis methods.This product has two clear advantages related to its potential competitors. Nowadays, all other potential diagnosis methods are based on polymerase chain reaction (PCR) procedures. This has clear weaknesses- given that it requires a biopsy. It is thus considered an invasive diagnostic method. Furthermore, in order to detect a gene mutation, PCR requires advance knowledge of which DNA/RNA sequence you are targeting. Secondly, its accuracy detection is lower than eLB. PCR accuracy can also only be improved slightly by amplifying the sample. In contrast, eLB only amplifies the signal reducing time-consumption and costs. Overall, the PCR diagnostic method is costly at around US$450 in China and is especially time-consuming, taking between 10-14 days. By contrast, SABER dx is expected to cost around US$50 and takes no more than 30 minutes.The company is expected to start manufacturing its product in summer 2016. This new revolutionary product can be used in either hospitals or center labs. Unfortunately, for hospitals, the company is still working on the necessary administrative steps to begin commercializing its product. However, center labs, which determine their own regulations can being reaping the benefits of this new product as soon as it enters the market.reporter| Jopevi 

如果您想对接动脉网所报道的企业,请填写表单,我们的工作人员将尽快为您服务。


注:文中如果涉及企业数据,均由受访者向分析师提供并确认。如果您有资源对接,联系报道项目,可以点击链接填写基本信息,我们将尽快与您联系。

声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

分享

微信扫描二维码分享文章

企业
对接
商务
合作
用户
反馈